Validation and application of a custom-designed targeted next-generation sequencing panel for the diagnostic mutational profiling of solid tumors

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Froyen, Guy ^a   Broekmans, An ^a   Hillen, Femke ^a   Pat, Karin ^a   Achten, Ruth ^a   Mebis, Jeroen ^a   Rummens, Jean Luc ^a   Willemse, Johan ^a,b   Maes, Brigitte ^a  

^a JESSA HOSPITAL   (Belgium)

^b AZ Turnhout ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN P53; SMAD4 PROTEIN; UNCLASSIFIED DRUG;

AKT1 GENE; AMPLICON; APC GENE; ARTICLE; BRAF GENE; CANCER PROGNOSIS; CDKN2A GENE; COLORECTAL CARCINOMA; COST EFFECTIVENESS ANALYSIS; EGFR GENE; ERBB2 GENE; EXON; FBXW7 GENE; GENE; GENE FREQUENCY; GNA11 GENE; HUMAN; HUMAN TISSUE; KIT GENE; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MAP2K1 GENE; MEASUREMENT ACCURACY; MELANOMA; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; ONCOGENE N RAS; PIK3CA GENE; PTEN GENE; SENSITIVITY AND SPECIFICITY; SMAD4 GENE; SOMATIC MUTATION; TP53 GENE; VALIDATION STUDY; GENETICS; HIGH THROUGHPUT SEQUENCING; MUTATION; NEOPLASMS; REPRODUCIBILITY;

HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LIMIT OF DETECTION; MUTATION; NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84964584615     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0154038     Document Type: Article

References (35)

1. Garraway LA, Verweij J, Ballman KV Precision oncology: an overview. J Clin Oncol 2013; 31:1803-1805. doi: 10.1200/JCO.2013.49.4799 PMID: 23589545
2. Mendelsohn J Personalizing oncology: perspectives and prospects. J Clin Oncol 2013; 31:1904-1911. doi: 10.1200/JCO.2012.45.3605 PMID: 23589547
3. Simon R, Roychowdhury S Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov 2013; 12:358-369. doi: 10.1038/nrd3979 PMID: 23629504
4. Gagan J, Van Allen EM Next-generation sequencing to guide cancertherapy. Genome Med 2015; 7:80. doi: 10.1186/s13073-015-0203-x PMID: 26221189
5. Thomas A, Rajan A, Lopez-Chavez A, Wang Y, Giaccone G From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. Ann Oncol 2013; 24:577-585. doi: 10.1093/annonc/mds478 PMID: 23131389
6. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013; 31:1023-1031. doi: 10.1038/nbt.2696 PMID: 24142049
7. Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, et al. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist 2014; 19:616-622. doi: 10.1634/theoncologist.2014-0011 PMID: 24797823
8. Singh RR, Patel KP, Routbort MJ, Reddy NG, Barkoh BA, Handal B, et al. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn 2013; 15:607-622. doi: 10.1016/j.jmoldx.2013.05.003 PMID: 23810757
9. Cottrell CE, Al-Kateb H, Bredemeyer AJ, Duncavage EJ, Spencer DH, Abel HJ, et al. Validation of a next-generation sequencing assay for clinical molecular oncology. J Mol Diagn 2014; 16:89-105. doi: 10.1016/j.jmoldx.2013.10.002 PMID: 24211365
10. Sie D, Snijders PJ, Meijer GA, Doeleman MW, van Moorsel MI, van Essen HF, et al. Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology. Cell Oncol 2014; 37:353-361.
11. Damodaran S, Berger MF, Roychowdhury S Clinical tumor sequencing: opportunities and challenges for precision cancer medicine. Am Soc Clin Oncol Educ Book 2015; 35:e175-e182.
12. Luthra R, Chen H, Roy-Chowdhuri S, Singh RR Next-Generation Sequencing in Clinical Molecular Diagnostics of Cancer: Advantages and Challenges. Cancers (Basel) 2015; 7:2023-2036.
13. Pant S, Weiner R, Marton MJ Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics. Front Oncol 2014; 4:78. doi: 10.3389/fonc.2014.00078 PMID: 24860780
14. Gargis AS, Kalman L, Berry MW, Bick DP, Dimmock DP, Hambuch T, et al. Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat Biotechnol 2012; 30:1033-1036. doi: 10.1038/nbt.2403 PMID: 23138292
15. Aziz N, Zhao Q, Bry L, Driscoll DK, Funke B, Gibson JS, et al. College of American Pathologists' laboratory standards for next-generation sequencing clinical tests. Arch Pathol Lab Med 2015; 139:481-493. doi: 10.5858/arpa.2014-0250-CP PMID: 25152313
16. Rehm HL, Bale SJ, Bayrak-Toydemir P, Berg JS, Brown KK, Deignan JL, et al. ACMG clinical laboratory standards for next-generation sequencing. Genet Med 2013; 15:733-747. doi: 10.1038/gim.2013.92 PMID: 23887774
17. Cuomo AM, Zucker HA, Dreslin S New York state department of Health: Next Generation Sequencing (NGS) guidelines for somatic genetic variant detection. 2015; http://www.wadsworth.org/labcert/TestApproval/forms/NextGenSeqONCOGuidelinespdf.
18. Bennett NC, Farah CS Next-generation sequencing in clinical oncology: next steps towards clinical validation. Cancers (Basel) 2014; 6:2296-2312.
19. Wong SQ, Fellowes A, Doig K, Ellul J, Bosma TJ, Irwin D, et al. Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients. Br J Cancer 2015; 112:1411-1420. doi: 10.1038/bjc.2015.80 PMID: 25742471
20. Hagemann IS, Devarakonda S, Lockwood CM, Spencer DH, Guebert K, Bredemeyer AJ, et al. Clinical next-generation sequencing in patients with non-small cell lung cancer. Cancer 2015; 121:631-639. doi: 10.1002/cncr.29089 PMID: 25345567
21. Ross JS, Wang K, Gay L, Otto GA, White E, Iwanik K, et al. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies. JAMA Oncol 2015; 1:40-49. doi: 10.1001/jamaoncol.2014.216 PMID: 26182302
22. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 2012; 18:6373-6383. doi: 10.1158/1078-0432.CCR-12-1627 PMID: 22966018
23. Zutter MM, Bloom KJ, Cheng L, Hagemann IS, Kaufman JH, Krasinskas AM, et al. The Cancer Genomics Resource List 2014. Arch Pathol Lab Med 2015; 139:989-1008. doi: 10.5858/arpa.2014-0330-CP PMID: 25436904
24. Ananda G, Mockus S, Lundquist M, Spotlow V, Simons A, Mitchell T, et al. Development and validation of the JAX Cancer Treatment Profile for detection of clinically actionable mutations in solid tumors. Exp Mol Pathol 2015; 98:106-112. doi: 10.1016/j.yexmp.2014.12.009 PMID: 25562415
25. Wang M, Escudero-Ibarz L, Moody S, Zeng N, Clipson A, Huang Y, et al. Somatic Mutation Screening Using Archival Formalin-Fixed, Paraffin-Embedded Tissues by Fluidigm Multiplex PCR and Illumina Sequencing. J Mol Diagn 2015; 17:521-532. doi: 10.1016/j.jmoldx.2015.04.008 PMID: 26165823
26. Erdmann J All aboard: Will molecular tumor boards help cancer patients? Nat Med 2015; 21:655-656. doi: 10.1038/nm0715-655 PMID: 26151320
27. Dienstmann R, Dong F, Borger D, Dias-Santagata D, Ellisen LW, Le LP, et al. Standardized decision support in next generation sequencing reports of somatic cancer variants. Mol Oncol 2014; 8:859-873. doi: 10.1016/j.molonc.2014.03.021 PMID: 24768039
28. Lee LA, Arvai KJ, Jones D Annotation of Sequence Variants in Cancer Samples: Processes and Pitfalls for Routine Assays in the Clinical Laboratory. J Mol Diagn 2015; 17:339-351. doi: 10.1016/j.jmoldx.2015.03.003 PMID: 25977238
29. Damodaran S, Miya J, Kautto E, Zhu E, Samorodnitsky E, Datta J, et al. Cancer Driver Log (CanDL): Catalog of Potentially Actionable Cancer Mutations. J Mol Diagn 2015; 17:554-559. doi: 10.1016/j.jmoldx.2015.05.002 PMID: 26320871
30. Bai J, Gao J, Mao Z, Wang J, Li J, Li W, et al. Genetic mutations in human rectal cancers detected by targeted sequencing. J Hum Genet 2015; 60:589-596. doi: 10.1038/jhg.2015.71 PMID: 26134512
31. Zhang L, Chen L, Sah S, Latham GJ, Patel R, Song Q, et al. Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing. Oncologist 2014; 19:336-343. doi: 10.1634/theoncologist.2013-0180 PMID: 24664487
32. Tuononen K, Maki-Nevala S, Sarhadi VK, Wirtanen A, Ronty M, Salmenkivi K, et al. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinomasuperiority of NGS. Genes Chromosomes Cancer 2013; 52:503-511. doi: 10.1002/gcc.22047 PMID: 23362162
33. Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, et al. Beyond BRAF (V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol 2015; 135:508-515. doi: 10.1038/jid.2014.366 PMID: 25148578
34. Scarpa A, Sikora K, Fassan M, Rachiglio AM, Cappellesso R, Antonello D, et al. Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel. PLoS One 2013; 8:e80478. doi: 10.1371/journal.pone.0080478 PMID: 24236184
35. Han SW, Kim HP, Shin JY, Jeong EG, Lee WC, Lee KH, et al. Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing. PLoS One 2013; 8:e64271. doi: 10.1371/journal.pone.0064271 PMID: 23700467